[{"Assets_0_Q1_USD":500794000.0,"CommonStockSharesOutstanding_0_Q1_shares":39873285.0,"EarningsPerShareBasic_1_Q1_USD":-0.46,"EarningsPerShareDiluted_1_Q1_USD":-0.46,"NetIncomeLoss_1_Q1_USD":-18378000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":38432000.0,"StockholdersEquity_0_Q1_USD":299475000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":39657418.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":39657418.0,"Ticker":"TVTX","CIK":"1438533","name":"RETROPHIN, INC.","OfficialName":"Travere Therapeutics Inc. Common Stock","form":"10-Q","period":"20180331","fy":"2018.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1905907401.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180501"}]